













WHAT IS CLAIMED IS:

1. A compound of **Formula 1**, **Formula 2**, **Formula 3** or of **Formula 4**

**Formula 1****Formula 2****Formula 3****Formula 4**

or isomers of the compounds of **Formulas 2 and 3** where the OCH_3 , and HF_2CO groups, respectively are linked to the 6 position of the benzimidazole ring, and
 wherein **R** represents the groups selected from Formulas (i) through (viii);
 the dashed line represents the bond connecting the **R** group with the SO_2 group,



Y is a straight chained or branch-chained disubstituted alkyl group of 1 to 8 carbons, or **Y** is N;

R₁ and **R₂** independently are H, a straight chained or branch-chained di- or trisubstituted alkyl group of 1 to 12 carbons including 1 or two **R₅** groups, or a straight chained or branch-chained saturated hydrocarbon skeleton having no more than 12 carbons including 1 or two **R₅** groups and optionally further including one to three **X** groups where **X** is independently selected from the group consisting of -O-, -S-, -NR₆-, -NHCO-, -CONH-, -CONHCO-, -COO-, -OCO- and a disubstituted phenyl group which can optionally be substituted with one or two halogen atoms or with one or two **R₃** groups; or the **R₅** group is directly attached without an intervening **R₁** or **R₂** group to the aromatic or heteroaromatic ring or to the **Y** group of formulas (i) through (viii);

R₃ and **R₄** independently are H, alkyl of 1 to 3 carbons, fluoroalkyl of 1 to 3 carbons, O-alkyl of 1 to 3 carbons, O-fluoroalkyl of 1 to 3 carbons, S-alkyl of 1 to 3 carbons, S-fluoroalkyl of 1 to 3 carbons;

R₅ is independently H, COOH or a tetrazole moiety;

R₆ is H or alkyl of 1 to 3 carbons;

with the provisos that

at least one the **R₁** and **R₂** groups is not H, and

at least one **R₅** is not H and no more than two **R₅** groups are COOH or tetrazole whereby the compound includes at least one but no more than two COOH or tetrazole groups;

when **Y** is -N then neither of the **R₁** and **R₂** groups is H,

or a pharmaceutically acceptable salt of said compound.

2. A compound in accordance with Claim 1 which has the structure in accordance with **Formula 1**.

3. A compound in accordance with Claim 1 which has the structure in accordance with **Formula 2**.

4. A compound in accordance with Claim 1 which has the structure in accordance with **Formula 3**.

5. A compound in accordance with Claim 1 which has the structure in accordance with **Formula 4**.

6. A compound in accordance with Claim 1 where R_5 is independently selected from H and COOH, or a pharmaceutically acceptable salt of said compound.

7. A compound in accordance with Claim 1 where the formula includes at least one X group.





8. A compound in accordance with Claim 1 where at least one X is O.

9. A compound in accordance with Claim 1 where at least one X is CONH.

9. A compound in accordance with Claim 1 having two R_5 groups which represent COOH, or a pharmaceutically acceptable salt of said compound.

10. A compound in accordance with Claim 1 where R represents **formula (i)**.

11. A compound of **Formula 1a**, **Formula 2a**, **Formula 3a** or of **Formula 4a**

**Formula 1a****Formula 2a****Formula 3a****Formula 4a**

or isomers of the compounds of **Formulas 2a** and **3a** where the OCH_3 , and HF_2CO groups, respectively are linked to the 6 position of the benzimidazole ring,

R_1 and R_2 independently are H, a straight chained or branch-chained di- or trisubstituted alkyl group of 1 to 12 carbons including 1 or two R_5 groups, or a straight chained or branch-chained saturated hydrocarbon skeleton having no more than 12 carbons including 1 or two R_5 groups and optionally further including one to three X groups where X is independently selected from the group consisting of -O-, -S-, -NR₆-, -NHCO-, -CONH-, -CONHCO-, -COO-, -OCO- and a disubstituted phenyl group which can optionally be substituted with one or two halogen atoms or with one or two R_3 groups; or the R_5 group is directly attached without an intervening R_1 or R_2 group to the aromatic or heteroaromatic ring or to the Y group of formulas (i) through (viii);

R_3 and R_4 independently are H, alkyl of 1 to 3 carbons, fluoroalkyl of 1 to 3 carbons, O-alkyl of 1 to 3 carbons, O-fluoroalkyl of 1 to 3 carbons, S-alkyl of 1 to 3 carbons, S-fluoroalkyl of 1 to 3 carbons;

R_5 is independently H or COOH;

R_6 is H or alkyl of 1 to 3 carbons;

with the provisos that

at least one the R_1 and R_2 groups is not H, and

at least one R_5 is not H and no more than two R_5 groups are COOH whereby the compound includes at least one but no more than two COOH groups;

or a pharmaceutically acceptable salt of said compound.

12. A compound in accordance with Claim 11 that has **Formula 1a**.

13. A compound in accordance with Claim 11 that has **Formula 2a**.

14. A compound in accordance with Claim 13 where the CH₃O group is in the 5 position of the benzimidazole moiety.

15. A compound in accordance with Claim 11 that has **Formula 3a**.

16. A compound in accordance with Claim 13 where the HF₂CO group

is in the 5 position of the benzimidazole moiety.





17. A compound in accordance with Claim 11 that has **Formula 4a**.

18. A compound in accordance with Claim 11 that includes only one COOH group, or its pharmaceutically acceptable salt.

19. A compound in accordance with Claim 11 that includes only two COOH groups, or its pharmaceutically acceptable salt.



20. A compound in accordance with Claim 11 where R_2 , R_3 and R_4 are hydrogen and R_1 is OCH_2COOH attached in the 4 position on the phenyl ring relative to the sulfonyl group, or its pharmaceutically acceptable salt.


21. A compound of **Formula 1**, **Formula 2**, **Formula 3** or of **Formula**

**Formula 1****Formula 2****Formula 3****Formula 4**

or isomers of the compounds of **Formulas 2** and **3** where the OCH_3 , and HF_2CO groups, respectively are linked to the 6 position of the benzimidazole ring, and

wherein **R** represents the groups selected from **Formulas (a)** through **(s)**, the dashed line represents the bond connecting the **R** group with the SO_2 group,





or a pharmaceutically acceptable salt of said compound.

22. A compound in accordance with Claim 21 of **Formula 1**.

23. A compound in accordance with Claim 21 of **Formula 2**.

24. A compound in accordance with Claim 23 where the CH_3O group is in the 5 position of the benzimidazole moiety.


25. A compound in accordance with Claim 21 of **Formula 3**.

26. A compound in accordance with Claim 25 where the HF_2O group is

in the 5 position of the benzimidazole moiety.

27. A compound in accordance with Claim 21 of **Formula 4**.

28. A compound in accordance with Claim 21 that has the formula



or a pharmaceutically acceptable salt of said compound.

29. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 1.

30. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 11.

31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 21.

32. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 28.

33. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 1, 11, 21 or 28 and a proton pump inhibitor drug selected from the groups consisting of the formulas (w), (x) (y) and (z)

